Cargando…
Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer
With the increasing number of available predictive biomarkers, clinical management of cancer is becoming increasingly reliant on the accurate serial monitoring of tumor genotypes. We tested whether tumor-specific copy number changes can be inferred from the peripheral blood of patients with cancer....
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708119/ https://www.ncbi.nlm.nih.gov/pubmed/23319339 http://dx.doi.org/10.1002/ijc.28030 |
_version_ | 1782276583694794752 |
---|---|
author | Heitzer, Ellen Auer, Martina Hoffmann, Eva Maria Pichler, Martin Gasch, Christin Ulz, Peter Lax, Sigurd Waldispuehl-Geigl, Julie Mauermann, Oliver Mohan, Sumitra Pristauz, Gunda Lackner, Carolin Höfler, Gerald Eisner, Florian Petru, Edgar Sill, Heinz Samonigg, Hellmut Pantel, Klaus Riethdorf, Sabine Bauernhofer, Thomas Geigl, Jochen B Speicher, Michael R |
author_facet | Heitzer, Ellen Auer, Martina Hoffmann, Eva Maria Pichler, Martin Gasch, Christin Ulz, Peter Lax, Sigurd Waldispuehl-Geigl, Julie Mauermann, Oliver Mohan, Sumitra Pristauz, Gunda Lackner, Carolin Höfler, Gerald Eisner, Florian Petru, Edgar Sill, Heinz Samonigg, Hellmut Pantel, Klaus Riethdorf, Sabine Bauernhofer, Thomas Geigl, Jochen B Speicher, Michael R |
author_sort | Heitzer, Ellen |
collection | PubMed |
description | With the increasing number of available predictive biomarkers, clinical management of cancer is becoming increasingly reliant on the accurate serial monitoring of tumor genotypes. We tested whether tumor-specific copy number changes can be inferred from the peripheral blood of patients with cancer. To this end, we determined the plasma DNA size distribution and the fraction of mutated plasma DNA fragments with deep sequencing and an ultrasensitive mutation-detection method, i.e., the Beads, Emulsion, Amplification, and Magnetics (BEAMing) assay. When analyzing the plasma DNA of 32 patients with Stage IV colorectal carcinoma, we found that a subset of the patients (34.4%) had a biphasic size distribution of plasma DNA fragments that was associated with increased circulating tumor cell numbers and elevated concentration of mutated plasma DNA fragments. In these cases, we were able to establish genome-wide tumor-specific copy number alterations directly from plasma DNA. Thus, we could analyze the current copy number status of the tumor genome, which was in some cases many years after diagnosis of the primary tumor. An unexpected finding was that not all patients with progressive metastatic disease appear to release tumor DNA into the circulation in measurable quantities. When we analyzed plasma DNA from 35 patients with metastatic breast cancer, we made similar observations suggesting that our approach may be applicable to a variety of tumor entities. This is the first description of such a biphasic distribution in a surprisingly high proportion of cancer patients which may have important implications for tumor diagnosis and monitoring. |
format | Online Article Text |
id | pubmed-3708119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-37081192013-07-12 Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer Heitzer, Ellen Auer, Martina Hoffmann, Eva Maria Pichler, Martin Gasch, Christin Ulz, Peter Lax, Sigurd Waldispuehl-Geigl, Julie Mauermann, Oliver Mohan, Sumitra Pristauz, Gunda Lackner, Carolin Höfler, Gerald Eisner, Florian Petru, Edgar Sill, Heinz Samonigg, Hellmut Pantel, Klaus Riethdorf, Sabine Bauernhofer, Thomas Geigl, Jochen B Speicher, Michael R Int J Cancer Cancer Genetics With the increasing number of available predictive biomarkers, clinical management of cancer is becoming increasingly reliant on the accurate serial monitoring of tumor genotypes. We tested whether tumor-specific copy number changes can be inferred from the peripheral blood of patients with cancer. To this end, we determined the plasma DNA size distribution and the fraction of mutated plasma DNA fragments with deep sequencing and an ultrasensitive mutation-detection method, i.e., the Beads, Emulsion, Amplification, and Magnetics (BEAMing) assay. When analyzing the plasma DNA of 32 patients with Stage IV colorectal carcinoma, we found that a subset of the patients (34.4%) had a biphasic size distribution of plasma DNA fragments that was associated with increased circulating tumor cell numbers and elevated concentration of mutated plasma DNA fragments. In these cases, we were able to establish genome-wide tumor-specific copy number alterations directly from plasma DNA. Thus, we could analyze the current copy number status of the tumor genome, which was in some cases many years after diagnosis of the primary tumor. An unexpected finding was that not all patients with progressive metastatic disease appear to release tumor DNA into the circulation in measurable quantities. When we analyzed plasma DNA from 35 patients with metastatic breast cancer, we made similar observations suggesting that our approach may be applicable to a variety of tumor entities. This is the first description of such a biphasic distribution in a surprisingly high proportion of cancer patients which may have important implications for tumor diagnosis and monitoring. Blackwell Publishing Ltd 2013-07-15 2013-01-15 /pmc/articles/PMC3708119/ /pubmed/23319339 http://dx.doi.org/10.1002/ijc.28030 Text en Copyright © 2013 UICC http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Cancer Genetics Heitzer, Ellen Auer, Martina Hoffmann, Eva Maria Pichler, Martin Gasch, Christin Ulz, Peter Lax, Sigurd Waldispuehl-Geigl, Julie Mauermann, Oliver Mohan, Sumitra Pristauz, Gunda Lackner, Carolin Höfler, Gerald Eisner, Florian Petru, Edgar Sill, Heinz Samonigg, Hellmut Pantel, Klaus Riethdorf, Sabine Bauernhofer, Thomas Geigl, Jochen B Speicher, Michael R Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer |
title | Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer |
title_full | Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer |
title_fullStr | Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer |
title_full_unstemmed | Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer |
title_short | Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer |
title_sort | establishment of tumor-specific copy number alterations from plasma dna of patients with cancer |
topic | Cancer Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708119/ https://www.ncbi.nlm.nih.gov/pubmed/23319339 http://dx.doi.org/10.1002/ijc.28030 |
work_keys_str_mv | AT heitzerellen establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT auermartina establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT hoffmannevamaria establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT pichlermartin establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT gaschchristin establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT ulzpeter establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT laxsigurd establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT waldispuehlgeigljulie establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT mauermannoliver establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT mohansumitra establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT pristauzgunda establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT lacknercarolin establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT hoflergerald establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT eisnerflorian establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT petruedgar establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT sillheinz establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT samonigghellmut establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT pantelklaus establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT riethdorfsabine establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT bauernhoferthomas establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT geigljochenb establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer AT speichermichaelr establishmentoftumorspecificcopynumberalterationsfromplasmadnaofpatientswithcancer |